Key Points
- Buzzers and Thizziez are different products. Both have been marketed through the alternative botanical and smoke-shop marketplace, but their ingredient claims and available testing evidence differ substantially.
- Buzzers have been linked to dangerous undisclosed opioids. Utah authorities identified mitragynine pseudoindoxyl (MGPI) and MGM-15 in tested Buzzers Cat’s Claw tablets.
- Fatal overdoses have prompted official warnings. Utah investigators connected Buzzers products with serious incidents, including a death investigation, and later reported four deaths involving potent kratom-related compounds across the state.
- Thizziez are marketed as proprietary ketone tablets. Retail descriptions advertise a 3,000 mg blend while claiming the product contains no kratom, THC, CBD, or mushrooms.
- Published Thizziez laboratory results leave important questions unanswered. Testing found no detectable amounts of several screened substances, but the reports do not establish the identity of the proprietary ketone blend.
- A label claiming “no kratom” or “no 7-OH” is not proof of safety. Manufacturers may use unfamiliar chemical names, broad proprietary descriptions, or alternative botanical branding that does not adequately explain a product’s effects.
- How Brooks Helps: Brooks Healing Center provides medical detox, residential addiction treatment, Medication-Assisted Treatment (MAT), Partial Hospitalization Program (PHP) services, and continuing recovery support for people experiencing problems with opioids, 7-OH, kratom-derived compounds, or other substances.
Gas stations, smoke shops, vape stores, and online retailers have increasingly become outlets for products marketed as alternatives to kratom, 7-hydroxymitragynine (7-OH), and other psychoactive substances. Among the products attracting attention are Buzzers and Thizziez, two flavored tablet products sold with descriptions that leave consumers asking what they actually contain.
At first glance, products like these may appear to be ordinary botanical supplements. Their packaging, flavor names, and alternative wellness language can create the impression that they are different from conventional drugs. However, recent investigations have demonstrated why consumers should evaluate the actual chemical ingredients and laboratory findings rather than relying on branding alone.
For Buzzers, the concern is supported by government laboratory testing that identified powerful opioid-active chemicals. For Thizziez, the central concern is uncertainty surrounding the ingredients described as a proprietary ketone blend.
Understanding the difference is particularly important as Tennessee and federal authorities continue responding to the growing market for concentrated kratom compounds, synthetic opioids, and products marketed as alternatives to 7-OH.
What Are Buzzers and Thizziez Tablets?
Understanding Two Products Marketed Through the Alternative Botanical Industry
Buzzers and Thizziez are flavored tablet products associated with a marketplace that also sells kratom-related extracts, cannabinoids, botanical supplements, and other psychoactive products.
Although both are promoted as alternatives to more familiar substances, they are not interchangeable products. Their descriptions, ingredient claims, and laboratory evidence need to be examined separately.
Buzzers tablets have been marketed using Cat’s Claw branding and proprietary botanical extract descriptions. The brand’s website describes formulations intended to produce experiences resembling those associated with kratom, while maintaining that the products do not rely on ordinary kratom ingredients.
Thizziez tablets, also appearing under the spelling Thizzies in published laboratory documentation, are advertised as containing a proprietary ketone blend. Retail listings describe the product as containing 3,000 mg of this blend per tablet and claim that it excludes kratom, THC, CBD, and mushrooms.
The central issue is that neither a proprietary product name nor a milligram quantity identifies the pharmacologically active chemicals responsible for an advertised experience.
For Buzzers, government testing has answered part of that question. For Thizziez, the publicly available evidence is considerably less definitive.
What Did Government Testing Find in Buzzers Tablets?
Utah Confirmed MGPI and MGM-15 in Products Labeled as Cat’s Claw
On July 30, 2026, the Utah Department of Agriculture and Food and the Utah Poison Control Center issued a warning about Buzzers Cat’s Claw tablets following severe health incidents and an investigation involving a death.
According to the Utah Department of Agriculture and Food, laboratory testing identified two opioid-active compounds:
- Mitragynine pseudoindoxyl (MGPI): A potent kratom-related compound associated with 7-OH chemistry and activity at opioid receptors.
- MGM-15: Also called dihydro-7-hydroxymitragynine, a manufactured compound related to 7-OH with opioid activity.
Neither substance is an ordinary component of genuine Cat’s Claw supplements.
Utah officials reported finding these compounds in multiple flavors of the tested Buzzers products. Authorities recommended that consumers avoid purchasing or consuming Buzzers Cat’s Claw tablets.
The findings are significant because the products were marketed using terminology that did not accurately communicate their opioid-related contents.
Four Deaths Prompted an Additional Public-Health Warning
On October 5, 2026, the Utah Department of Health and Human Services issued another warning following four deaths across Utah associated with potent kratom-derived compounds found in certain herbal products.
The agency again highlighted products sold under names such as Buzzers and identified MGPI and MGM-15 as chemicals of particular concern.
Importantly, the announcement did not establish that all four deaths involved Buzzers. The broader fatalities involved dangerous compounds found across the affected product marketplace, while Buzzers had separately been identified in the earlier investigation.
These findings demonstrate why a product marketed as an herbal alternative can still present serious opioid overdose risks.
Brooks previously examined the regional implications in our article on Cat’s Claw products potentially disguising 7-OH-related opioids, including the appearance of Buzzers and similar products in Middle Tennessee.
What Is Actually Inside Thizziez Ketone Tablets?
What the Proprietary Ketone Blend Claims to Contain
Thizziez presents a different scientific question.
Retail descriptions advertise Thizziez as an alternative tablet made with a proprietary ketone formulation. The advertised ingredients include the ketone blend, binders, microcrystalline cellulose, magnesium stearate, silica oxide, dicalcium phosphate, and food-grade colorants.
The marketing also claims that the tablets contain no kratom extracts, THC, CBD, or mushrooms.
However, the description does not clearly identify the individual chemicals making up the proprietary ketone blend.
The word ketone describes a broad category of chemical compounds characterized by a particular molecular structure. It is not the name of one specific substance, and the presence of a ketone functional group alone does not establish a product’s pharmacological properties.
For this reason, a statement that a tablet contains 3,000 mg of a proprietary ketone blend does not establish what the active ingredients are, how they work, or whether they have been adequately studied in humans.
Without that information, consumers cannot reliably determine the product’s intended biological mechanism or compare its effects with more familiar substances.
What Do the Published Thizziez Laboratory Reports Show?
A published laboratory report for ExoClub Thizzies ketone tablets contains testing completed by Excelbis Labs in February 2026.
The document includes results for several flavored samples, including peach, mango, citrus, and strawberry.
The testing reported no detectable amounts of several screened substances, including:
- 7-hydroxymitragynine (7-OH)
- Mitragynine
- Psilocybin
- Psilocin
- Muscimol
- Several additional kratom and mushroom-related alkaloids
The report also contains testing categories addressing cannabinoids and various contaminants.
Those findings provide information about the specific samples and substances included in the laboratory screening. They do not establish that every tablet sold under the brand name contains identical ingredients.
There is also a particularly important limitation: the published screening panel does not identify the proprietary ketone blend itself.
The reviewed alkaloid panel does not specifically list MGPI or MGM-15. Therefore, it cannot be used to establish the absence of those particular compounds.
That limitation does not mean Thizziez contains MGPI, MGM-15, or any other undisclosed opioid. It means the available report does not answer those questions.
Likewise, a laboratory result marked “not detected” means the specified substance was not identified above the method’s detection limit in the tested sample. It does not establish the absence of every possible psychoactive chemical.
At the time of this review, the cited public-health findings involving Buzzers should not be interpreted as evidence that Thizziez has been implicated in the same confirmed overdose investigations.
Buzzers vs. Thizziez: A Comparison of Ingredients and Laboratory Evidence
What Has Been Confirmed, What Is Advertised, and What Remains Unknown
| Category | Buzzers | Thizziez |
|---|---|---|
| Product type | Flavored botanical extract tablets | Flavored proprietary ketone tablets |
| Advertised ingredient description | Cat’s Claw and proprietary botanical extracts | Proprietary ketone blend |
| Advertised strength | Varies by product | Listings describe 3,000 mg per tablet |
| Government laboratory findings | MGPI and MGM-15 found in tested Buzzers Cat’s Claw products | No equivalent government finding identified in the sources reviewed |
| Public laboratory documentation | Brand-associated reports exist, but government testing established concerning undeclared compounds in investigated products | Published Excelbis reports include screening for selected alkaloids and contaminants |
| Confirmed opioid-related concern | Yes, involving tested products | Not established by the reviewed sources |
| Principal uncertainty | Whether products and batches accurately disclose their composition | Identity and pharmacological effects of the proprietary ketone blend |
| FDA-approved treatment product | No | No |
The distinction between these two products is not that one has been established as safe while the other has not.
Instead, the available evidence establishes a confirmed hazard involving tested Buzzers tablets and a separate, unresolved ingredient-transparency issue involving Thizziez.
That difference matters when interpreting laboratory results, evaluating advertising claims, or discussing possible medical risks.
Why “No Kratom” and “No 7-OH” Claims Can Be Misleading
Related Opioid Chemicals May Have Different Names and Structures
One of the most important lessons from the Buzzers investigation is that a label claiming a product contains no kratom or 7-OH does not necessarily exclude other potent kratom-related compounds.
Kratom contains several alkaloids, most notably mitragynine. One related compound, 7-hydroxymitragynine, acts on opioid receptors and has attracted substantial attention because of its potency and the rise of concentrated commercial formulations.
Manufactured or chemically modified compounds can differ from the original plant alkaloids while still interacting with opioid receptors.
MGPI and MGM-15 are examples of compounds associated with this expanding chemical family.
Consumers should not assume that a statement excluding one particular compound eliminates the possibility of another substance producing similar opioid effects.
Our earlier article comparing mitragynine pseudoindoxyl with 7-hydroxymitragynine explains why these compounds should be evaluated individually rather than treated as interchangeable names.
Why a Laboratory Certificate Does Not Automatically Establish Safety
Certificates of analysis, commonly called COAs, are useful documents when they come from qualified laboratories and clearly identify the tested samples, methods, detection limits, and analytes.
However, a COA is only as informative as the testing performed.
A screening report for cannabinoids, common mushroom compounds, pesticides, or heavy metals cannot automatically establish that a product contains no unfamiliar synthetic opioid.
Similarly, a report identifying the absence of 7-OH does not establish that MGPI, MGM-15, MGM-16, or other related chemicals are absent unless those substances were adequately tested.
The FDA explains in its guidance on dietary supplements that supplements generally do not undergo the same premarket safety and effectiveness approval process required for prescription drugs.
Consumers should therefore distinguish between a manufacturer’s marketing statements, a laboratory’s limited findings, and independent public-health testing that identifies specific hazards.
How Are Buzzers, 7-OH, MGPI, and MGM Compounds Related?
Understanding the Expanding Market for Kratom-Derived and Synthetic Alternatives
The emergence of products like Buzzers cannot be understood without examining the broader market for concentrated kratom-related compounds.
These substances have appeared in tablets, shots, gummies, and other products marketed for relaxation, euphoria, mood effects, or as alternatives to conventional opioids.
Several compounds are especially relevant.
7-Hydroxymitragynine (7-OH)
7-OH is an opioid-active kratom alkaloid that occurs naturally in small quantities but is also sold in concentrated or enhanced products. Its effects and potential for dependence differ considerably from those of ordinary botanical kratom.
Brooks examines this market in our guide to 7Tabz and concentrated 7-OH tablets, including concerns about potency, withdrawal, and inaccurate consumer assumptions.
Mitragynine Pseudoindoxyl (MGPI)
MGPI is a kratom-related compound associated with the chemical transformation of 7-OH. It interacts with opioid receptors and has attracted attention because of its pharmacological activity and appearance in newer products.
The presence of MGPI in tested Buzzers tablets is especially significant because consumers purchasing Cat’s Claw products would not necessarily expect exposure to a kratom-related opioid.
Brooks provides further information in our article exploring whether mitragynine pseudoindoxyl is stronger than 7-OH.
MGM-15
MGM-15, or dihydro-7-hydroxymitragynine, is a manufactured opioid-active compound related to 7-OH chemistry.
Utah investigators confirmed MGM-15 in the Buzzers Cat’s Claw products they tested. This makes it particularly relevant when evaluating the risks associated with mislabeled botanical tablets.
Readers can learn more in our separate guide, MGM-15: What to Know About This New Kratom-Derived Opioid.
MGM-16
MGM-16 is another manufactured compound related to 7-OH. Although it belongs to the same broader family of substances receiving regulatory attention, the public Utah findings cited above specifically identified MGPI and MGM-15 in tested Buzzers tablets.
It would be inaccurate to claim that those findings also confirmed MGM-16 in Buzzers without additional product-specific evidence.
Our MGM-16 vs. MGM-15 comparison explains their similarities, differences, and known risks.
Other Marketed Alternatives
The marketplace also includes products promoted using proprietary terms such as Mitraxidine, along with botanical products marketed as substitutes for kratom and 7-OH.
These names do not establish that the products contain the same ingredients. Nevertheless, they illustrate how rapidly the marketplace is changing.
Brooks has also examined Mitraxidine and its marketing as a 7-OH alternative and the concerns surrounding potentially adulterated products sold as kava.
The common concern is not that every alternative product contains the same chemical. It is that consumers may be unable to determine their actual exposure from marketing alone.
What Is the Legal Status of These Products in 2026?
Federal Scheduling Changes and Tennessee’s Kratom Restrictions
The legal environment surrounding kratom-related compounds has changed significantly during 2026.
The U.S. Drug Enforcement Administration temporarily placed MGPI, MGM-15, and MGM-16 into federal Schedule I effective August 26, 2026.
On October 9, the U.S. Department of Justice announced updated scheduling actions. Those actions included revised concentration and ratio thresholds proposed for 7-OH and MGPI, while maintaining the temporary controls already in effect during the new notice period.
At that time, the DEA had not yet issued a final temporary scheduling order specifically covering 7-OH under the revised approach.
The distinction is important because legal status may depend on the specific compound, its concentration, the formulation, and applicable federal or state requirements.
Tennessee has taken additional action.
According to the Tennessee Department of Mental Health and Substance Abuse Services, the state’s 2026 law prohibits the possession, manufacture, or sale of kratom beginning July 1, 2026.
That change is particularly relevant in Middle Tennessee, where products promoted as Cat’s Claw alternatives have appeared in the same retail environment previously occupied by kratom products.
Our earlier Buzzers and Cat’s Claw investigation described local observations by a Warren County prevention coalition in the McMinnville area. Those observations established that the products were being marketed locally, but they did not independently establish the composition of every Tennessee product.
A label claiming a product is legal nationwide should not be treated as an authoritative determination of its legal status.
Can Buzzers and Similar Products Cause an Opioid Overdose?
Recognizing the Signs of Dangerous Opioid Exposure
Products containing MGPI, MGM-15, or other potent opioid-active substances may cause dangerous sedation and respiratory depression.
Respiratory depression occurs when a substance interferes with the body’s normal drive to breathe. In severe cases, breathing can become dangerously slow or stop entirely.
Warning signs of a possible opioid overdose include:
- Inability to wake the person or obtain a normal response
- Slow, shallow, irregular, or absent breathing
- Unusual snoring, gurgling, or choking sounds
- Blue, gray, or unusually pale lips or fingernails
- Extreme drowsiness or loss of consciousness
- Limpness or unusual unresponsiveness
These symptoms should be treated as a medical emergency regardless of the product’s advertised ingredients.
The Washington Poison Center’s October 2026 safety alert warns that adulterated Cat’s Claw products can cause severe opioid toxicity and that routine urine drug screens may fail to identify the substances involved.
A negative routine drug screen therefore does not necessarily exclude exposure to an unfamiliar opioid.
What to Do if Someone May Be Overdosing
If someone becomes unresponsive or is not breathing normally after using Buzzers, a suspected opioid product, or an unidentified smoke-shop tablet:
- Call 911 immediately. Explain that the person may have taken an unidentified or mislabeled psychoactive product.
- Administer naloxone if available. Naloxone can reverse opioid-related respiratory depression, including overdoses involving many opioid-active substances.
- Support breathing and follow dispatcher instructions. Provide rescue breathing or CPR as directed, particularly if the person is not breathing normally.
- Stay with the person. Additional naloxone may be necessary, and symptoms can return after an initial improvement.
- Share the packaging with emergency personnel. Product names, ingredient descriptions, and identifying information can assist medical evaluation.
The Centers for Disease Control and Prevention recommends acting promptly when an opioid overdose is suspected rather than waiting for certainty about which substance was involved.
Naloxone is not a universal antidote for every psychoactive chemical. Nevertheless, it should be administered when opioid involvement is reasonably suspected, even if the exact ingredients are unknown.
Can Someone Develop Dependence on Buzzers or Other Alternative Tablets?
Opioid Receptor Activity, Withdrawal, and Repeated Exposure
Repeated exposure to opioid-active compounds can produce tolerance and physical dependence.
Tolerance occurs when a person requires increasing exposure to obtain effects that previously occurred at lower amounts. Physical dependence develops when the body adapts to repeated exposure and withdrawal symptoms emerge as those substances are reduced or discontinued.
For products containing potent kratom-related opioids, withdrawal may include:
- Anxiety and restlessness
- Sweating or chills
- Insomnia
- Muscle aches and discomfort
- Nausea, vomiting, or diarrhea
- Irritability
- Strong cravings
- Difficulty functioning without the substance
The severity of withdrawal varies according to the actual chemical exposure, frequency of use, other medications or substances involved, and the person’s medical history.
Our article on 7-OH withdrawal symptoms and timelines explains why concentrated kratom-related products can create significant dependence.
For Thizziez specifically, the reviewed public sources do not establish an opioid mechanism or a validated withdrawal profile. Symptoms following use should be medically evaluated rather than automatically attributed to 7-OH, ketones, or any other particular substance.
People using unidentified tablets regularly should avoid relying on online taper schedules or substituting another poorly characterized product to manage withdrawal.
A professional assessment can help identify the symptoms involved and determine whether medical withdrawal management or another form of care is appropriate.
Treatment for Dependence on Buzzers, 7-OH, and Related Opioid Products
Medical Detox and Evidence-Based Treatment at Brooks Healing Center
People experiencing dependence on concentrated kratom products, MGPI, MGM-15, or other opioid-active substances may need medical and behavioral-health support.
At Brooks Healing Center, treatment begins with an individualized assessment of the person’s symptoms, substance exposure, medical history, and recovery goals.
When clinically appropriate, treatment may include:
- Medical detox to provide supervised withdrawal management and stabilization.
- Residential addiction treatment for individuals who need structured support and a recovery-focused environment.
- Medication-Assisted Treatment (MAT) using FDA-approved medications when appropriate for the diagnosed condition and clinical circumstances.
- Partial Hospitalization Program (PHP) services for people who need substantial daytime treatment while living outside an overnight clinical setting.
- Continued therapy, relapse-prevention planning, and recovery support to help address the broader circumstances surrounding substance use.
For eligible patients with opioid use disorder, FDA-approved medications may include buprenorphine formulations such as Sublocade and Brixadi.
Both are extended-release injectable forms of buprenorphine used in the treatment of opioid use disorder.
The FDA recognizes buprenorphine as an established treatment for opioid use disorder, although these medications are not specifically FDA-approved for treating dependence on Buzzers, Thizziez, 7-OH, or MGPI as individual products or compounds.
Medication decisions must be individualized, especially when the exact substances involved are uncertain.
Treatment should address more than the immediate withdrawal period. For individuals struggling with cravings, repeated return to use, anxiety, depression, or other challenges, a comprehensive recovery plan can help build stability beyond initial medical treatment.
Frequently Asked Questions About Buzzers and Thizziez
Are Buzzers tablets really made from Cat’s Claw?
Buzzers has marketed products using Cat’s Claw and proprietary botanical extract descriptions. However, Utah authorities confirmed MGPI and MGM-15 in tested Buzzers Cat’s Claw tablets.
Those findings establish that certain investigated products contained potent kratom-related opioid compounds that were not adequately communicated by the herbal branding.
Do Thizziez tablets contain 7-OH?
A published February 2026 laboratory report for ExoClub Thizzies samples recorded no detectable 7-hydroxymitragynine in the samples and testing methods described.
That finding does not establish that every Thizziez tablet or future batch contains no 7-OH. It also does not fully identify the proprietary ketone formulation.
Do Thizziez tablets contain MGPI or MGM-15?
The published laboratory panel reviewed for this article does not specifically identify testing for MGPI or MGM-15.
Consequently, the report cannot establish whether those compounds are present or absent. There is also no basis in the reviewed evidence to claim that Thizziez contains the same opioid ingredients confirmed in the investigated Buzzers products.
Are Thizziez the same as ecstasy or MDMA?
The product name alone does not establish that Thizziez contains MDMA or another substance associated with the name “thizz.”
The publicly reviewed laboratory documentation does not establish an MDMA formulation. Consumers should not infer a product’s contents or expected effects from slang, branding, or its resemblance to other tablets.
Are Thizziez safe because the lab report says the samples passed?
No laboratory certificate can establish comprehensive safety simply by showing passing results in selected categories.
The Thizziez report provides results for certain screened chemicals and contaminants, but it does not establish the identity, medical safety, or expected psychoactive effects of the advertised proprietary ketone blend.
Did Buzzers cause four deaths in Utah?
Utah’s July 2026 warning connected investigated Buzzers Cat’s Claw tablets with severe health incidents and a death investigation.
The subsequent October announcement identified four deaths across Utah involving potent kratom-related compounds in the broader category of affected products. It did not establish that every one of those deaths involved Buzzers.
Are MGPI and MGM-15 the same as 7-OH?
No. MGPI, MGM-15, and 7-OH are chemically related but distinct compounds.
They may share opioid-receptor activity, yet differences in their chemistry and pharmacology prevent them from being treated as equivalent substances. Brooks provides additional comparisons in our articles about MGPI, MGM-15, and MGM-16.
Will Buzzers or Thizziez show up on a standard drug test?
Standard drug screening panels do not necessarily detect unfamiliar synthetic or semi-synthetic compounds.
Specialized toxicology testing may be necessary to identify certain kratom-related opioids. A negative routine drug screen does not establish that an unidentified tablet was harmless or free of psychoactive substances.
Can naloxone reverse an overdose involving Buzzers?
Because MGPI and MGM-15 are opioid-active compounds, naloxone is recommended when an opioid overdose involving these substances is suspected.
Call 911 immediately, administer naloxone if available, and follow emergency instructions. The response to naloxone and the need for additional medical intervention can vary, particularly when other substances are involved.
Can Brooks Healing Center help someone struggling with these products?
Yes. Brooks Healing Center provides individualized assessments and addiction treatment for people experiencing problems with opioid-active substances and other drug use.
The appropriate treatment plan depends on the substances involved, withdrawal symptoms, medical history, and overall clinical needs. An assessment is especially important when a person cannot confidently identify what a product contains.
Get Help for Kratom, 7-OH, and Emerging Opioid Dependence in Tennessee
Evidence-Based Care Without Relying on Unidentified Substances
The Buzzers investigation illustrates an important problem in the evolving market for psychoactive botanical alternatives: product names and ingredient claims do not always describe the chemicals consumers are actually taking.
Thizziez raises a related but different concern. Its proprietary ketone formulation remains insufficiently identified in the public laboratory documentation reviewed here, making it inappropriate to assume either a specific chemical composition or an established safety profile.
For people struggling with repeated use, withdrawal, cravings, or uncertainty about a product’s effects, there are better options than attempting to manage the situation with another unfamiliar substance.
Brooks Healing Center provides comprehensive addiction treatment between Nashville and Chattanooga in Normandy, Tennessee. Our team helps individuals and families understand their options for medical detox, residential treatment, MAT, PHP, and continued recovery care.
If you or someone you love is having difficulty stopping Buzzers, 7-OH, kratom-derived opioids, or another substance, call Brooks Healing Center at (931) 486-8824 to speak confidentially with our admissions team.
For a suspected overdose or another immediate medical emergency, call 911.
References
Centers for Disease Control and Prevention. (n.d.). What to do if you think someone is overdosing. https://www.cdc.gov/stop-overdose/response/
Excelbis Labs. (2026, February 19). ExoClub Thizzies: Laboratory analysis and certificates of analysis [Laboratory report]. https://greatcbdshop.com/wp-content/uploads/2026/03/Thizzies-Ketone-Tablets-3000mg-Lab-Analysis.pdf
The Calm Leaf. (n.d.). Thizziez ketone chewable tabs [Product listing]. https://www.thecalmleaf.com/thizziez-ketone-chewable-tabs/
U.S. Department of Health and Human Services. (2026, October 9). HHS recommends science-based thresholds to target dangerous enhanced kratom products. https://www.hhs.gov/press-room/hhs-recommends-thresholds-enhanced-kratom-products-7-oh-mgpi.html
U.S. Department of Justice. (2026, October 9). Department of Justice announces updates to emergency scheduling actions for 7-OH and related opioid substances. https://www.justice.gov/opa/pr/department-justice-announces-updates-emergency-scheduling-actions-7-oh-and-related-opioid
U.S. Food and Drug Administration. (n.d.). Hiding in plain sight: 7-OH products. https://www.fda.gov/news-events/public-health-focus/hiding-plain-sight-7-oh-products
U.S. Food and Drug Administration. (n.d.). Information about medications for opioid use disorder (MOUD). https://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/information-about-medications-opioid-use-disorder-moud
U.S. Food and Drug Administration. (2026). Questions and answers on dietary supplements. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
Utah Department of Agriculture and Food. (2026, July 30). Illegal kratom product sold in Utah County linked to death in Utah. https://ag.utah.gov/news/illegal-kratom-product-sold-in-utah-county-linked-to-death-in-utah/
Utah Department of Health and Human Services. (2026, October 5). Utah health officials warn of fatal overdoses involving illegal “cat’s claw” and kratom product. https://dhhs.utah.gov/featured-news/utah-health-officials-warn-of-fatal-overdoses-involving-illegal-cats-claw-and-kratom-product/
Utah Poison Control Center. (2026, July 22). Adulterated cat’s claw and kava products may cause opioid overdose. https://poisoncontrol.utah.edu/news/2026/07/adulterated-cats-claw-and-kava-products-may-cause-opioid-overdose
Tennessee Department of Mental Health and Substance Abuse Services. (n.d.). Emerging substances. https://www.tn.gov/behavioral-health/substance-abuse-services/prevention/emerging-substances.html
Washington Poison Center. (2026, October 7). Safety alert: Fake cat’s claw supplements resulting in overdose & severe illness. https://www.wapc.org/insights/safety-alert-fake-cats-claw/
Buzzers. (n.d.). Buzzers proprietary botanical extract tablets & bottles [Manufacturer website]. https://getbuzzers.com/
